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Tolerance without Clonal Expansion: Self-Antigen-Expressing
B Cells Program Self-Reactive T Cells for Future Deletion1
Friederike Frommer,* Tobias J. A. J. Heinen,† F. Thomas Wunderlich,†‡ Nir Yogev,*
Thorsten Buch,§ Axel Roers,¶ Estelle Bettelli, Werner Mu¨ller,# Stephen M. Anderton,**
and Ari Waisman2*
B cells have been shown in various animal models to induce immunological tolerance leading to reduced immune responses and
protection from autoimmunity. We show that interaction of B cells with naive T cells results in T cell triggering accompanied by
the expression of negative costimulatory molecules such as PD-1, CTLA-4, B and T lymphocyte attenuator, and CD5. Following
interaction with B cells, T cells were not induced to proliferate, in a process that was dependent on their expression of PD-1 and
CTLA-4, but not CD5. In contrast, the T cells became sensitive to Ag-induced cell death. Our results demonstrate that B cells
participate in the homeostasis of the immune system by ablation of conventional self-reactive T cells. The Journal of
Immunology, 2008, 181: 5748 –5759.
A mple evidence exists to suggest that B lymphocytes havean inhibitory influence on T cells. Fuchs and Matzinger(1) have demonstrated that transfer of male B cells in-
hibited HY Ag-specific CTL responses. Further, they also demon-
strated that activated B cells were potent inhibitory cells of CTL
responses. In contrast, naive as well as activated B cells were
shown to activate memory T cells rather than tolerizing them (1).
Targeting Ags to B cells in vivo also results in tolerance of T cells.
For example, injection of mice with rabbit anti-mouse IgD Ab
resulted in lower T cell-dependent immune responses to rabbit Ig
(2, 3). It was speculated that the anti-IgD Abs reached resting B
cells and epitopes of these Abs were presented by B cells leading
to tolerance of Ag-specific CD4 T cells.
B cells were previously shown to exhibit inhibitory function in
experimental autoimmune encephalomyelitis (EAE),3 a T cell-de-
pendent animal model of multiple sclerosis. Hence, rats injected
with mouse anti-IgD Abs, coupled to myelin basic protein (MBP)
were tolerized to MBP-induced EAE (4, 5). Similar to the exper-
iments of Eynon et al. (2), it was presumed that anti-IgD Abs
targeted resting B cells, and due to a lack of costimulatory mole-
cules, these B cells tolerized MBP-specific T cells. Similarly, it
was shown that passive transfer of B cells expressing a myelin
peptide prevented the induction of EAE (6–8) or even EAE re-
lapses (9). One explanation why B cells induce tolerance of naive
but not memory T cells might be the need for expression of co-
stimulatory molecules by the APC to activate naive T cells, spe-
cifically B7-1 and/or B7-2, but resting B cells do not express these
molecules. On the other hand, memory T cells may not need co-
stimulation and could therefore be activated by B cells. A problem
of this hypothesis is that also activated B cells, which normally do
express B7 molecules, can induce tolerance of T cells (10). It is
therefore not clear whether it is indeed the absence of costimula-
tion what causes B cells to induce tolerance.
To study the role of B cells in tolerance induction we have
generated mice that express an MHC class II-restricted immuno-
dominant T cell epitope of myelin oligodendrocyte glycoprotein
(MOG) specifically on B cells. These mice were found to be re-
sistant to EAE induction. We could show that, following interac-
tion of naive T cells with B cells presenting their specific Ag, T
cells are partially activated, resulting in very marginal proliferation
and up-regulation of coinhibitory molecules such as CTLA-4, B
and T lymphocyte attenuator (BTLA), PD-1, and CD5. Subsequent
in vivo activation of tolerized T cells leads to their deletion. Thus,
we assessed that naive B cells induce peripheral tolerance by in-
ducing expression of negative costimulatory molecules by Ag-spe-
cific T cells, followed by Ag-induced cell death (AICD) upon the
next Ag encounter.
Materials and Methods
Generation of invariant chain (Ii) MOG mice
The targeting vector ROSA26STOP*IiMOG was constructed by introduc-
tion into the XbaI site of the vector ROSA26–1 (11); a gift from P. Soriano
(Fred Hutchinson Cancer Research Center, Seattle, WA) of a fragment
comprising (5 to 3): adenoviral splice acceptor, loxP, 2 SV40 polyad-
enylation signal, FRT-flanked pGK-neo, a STOP cassette (12), loxP, mu-
tant invariant chain (termed IiMOG), and bovine poly(A). The mutant in-
variant chain (IiMOG) was generated by assembly PCR on Ii template
cDNA (derived from plasmid pcEX V3 mIi31, carrying the cDNA of the
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Ii splice form Ii31 (13), gift from N. Koch(University of Bonn, bonn,
Germany)) replacing the coding sequence of CLIP with the one of the
MOG peptide 35–55. First, two independent fragments were amplified con-
taining either the 5 or the 3 part of Ii (using the external primers LB-Ii
(5-ACATGTAGTACTGGATCCACCATGGATGACCAACGCGACC-3)
and RB-FLAG-Ii (5-GATATCATTTGTCGTCGTCGTCTTTGTAGTCC
AGGGTGACTTGACCCAGTTCCTGCC-3) and, introduced by the
primers ML-Ii and MR-Ii, the sequence of MOGp35–55 (ML-Ii: 5-CTTG
CCATTTCGGTAGAGGTGAACCACTCTTGAGAAGGGAGAACGGT
ACCAACCCACCTCCATCTTCATGCGAAGGCTCTCC-3; ML-Ii/B-
FLAG-Ii: 429 base pairs (bp); MR-Ii: 5-ATGGAGGTGGGTTGGTAC
CGTTCTCCCTTCTCAAGAGTGGTTCACCTCTACCGAAATGGCA
AGGATAACATGCTCCTTGGGCC-3; MR-Ii/LB-Ii: 321 bp). The two
fragments were assembled by PCR using the external primers LB-Ii and
RB-FLAG-Ii thereby generating the IiMOG minigene (688 bp). With the 5
primer (LB-Ii), a kozak consensus sequence as well as ScaI and AflIII
restriction sites were introduced. Along with the 3 primer (RB-FLAG-Ii), a
FLAG-tag sequence and an EcoRV restriction site were added to the 3 end of
the mutant Ii. The two fragments were assembled by PCR using the external
primers LB-Ii and RB-FLAG-Ii (688 bp). Eighty micrograms of targeting
vector was linearized with PvuI and electroporated into Bruce4 ES cells (14).
ES cell culture was performed as described (15). Homologous recombinants
were identified by Southern blot analysis using a 700bp genomic EcoRI-PacI
fragment after EcoRI digest (16) (data not shown). Chimeras were generated
from two homologous recombinant clones by injection into CB29 blastocysts.
Germline transmission was confirmed by Southern blot analysis after EcoRI
digest using a 1-kb SacII-XbaI fragment (probe 1; p1) from pROSA26-1 (17).
Mice
All animal experiments were in accordance with the guidelines of the cen-
tral animal facility institution (ZVTE, University of Mainz). 2D2 mice
were described elsewhere (18). DNA for typing was prepared from tail
biopsies. Presence of the different alleles was routinely tested by PCR as
published for CD19-Cre (19, 20) and 2D2 mice (18) or using the following
primer pairs: for IiMOG/IiMOG (982/456 bp product) 5-GGC TAC
TGC TGA CTC TCA ACA TT 3 (WSS-F), 5-ATT TCG GTA GAG
GTG AAC CAC TC 3 (MOG-R), and 5- CAG GGT TTC CTT GAT
GAT GTC A3 (Rosa-1). All experiments were performed with 6–12 wk
old mice. The experiments were repeated at least once.
Cell preparations and CFSE staining
2D2 CD4 T cells or B cells were isolated from spleen and lymph node by
positive selection using MACS (Miltenyi Biotec) according to the manu-
facturer’s instructions. Purity of the resulting CD4 T cells or CD19 B
cells was typically 95%. When indicated freshly isolated CD4 T cells
from 2D2 mice were labeled with the vital dye CFSE (Molecular Probes).
After washing the cells twice in 10 ml PBS (pH 7.4), they were incubated
with 0.5 mM CFSE in 1 ml PBS per 107 cells at room temperature for 8
min. To stop the staining reaction, 8 ml RPMI 1640 plus 10% FCS was
added. The cells were then washed twice in 10 ml RPMI 1640, resuspended
in the appropriate volume of PBS and typically 5–10  106 T cells were
injected i.v. into the different mice as indicated.
B and T cell activation
B cells were MACS-purified from BMOG mice using CD19 beads (Miltenyi
Biotec). B cells were activated in culture in the presence of anti-CD40 (2.5
g/ml; FGK45.5) (21), anti-BCR (10 g/ml; Bethyl Laboratories), and
IL-4 (2 g/ml; R&D Systems) for 4 h at 37°C. B cells were injected i.v. in
a concentration of 10  106/mouse. To obtain activated 2D2 CD4 T cells
for adoptive transfer, 2D2 mice were immunized as described for active
EAE induction, but no pertussis toxin was administered. Ten days after
immunization, mice were sacrificed, activated CD4 T cells from spleen
and lymph node were MACS-purified using Va3.2-bio Abs (BD Bio-
sciences), and streptavidin beads (Miltenyi Biotec) and 5–10  106 T cells
were i.v. injected into the recipient mice. To generate memory 2D2 CD4
T cells, activated 2D2 CD4 T cells were adoptively transferred to MOG-
deficient mice (MOGi-Cre homozygous) (22), re-isolated 30 days after
transfer using MACS, and the memory phenotype was assessed by FACS
analysis (CD44 CD62Lint). Three 106 T cells were i.v. injected into the
recipient mice.
Flow cytometry
For cytofluorometric analysis, we used Ab conjugates to the following Ags:
CD4, CD5, CD25, CD44, CD69, CD103, BTLA, CTLA-4, Fas, Ly6C,
PD-1, Tim-3, Thy1.1, Va3.2, and Vb11. Abs were obtained from BD
Pharmingen or Natutec (eBiosciences). Intracellular stainings for Foxp3
were performed using the Foxp3 Staining Set (Natutec, eBiosciences) ac-
cording to the manufacturer’s instructions. Anti-Gitr (clone DTA-1) was
prepared in our laboratory. Cells from lymphoid organs were stained with
the Ab conjugates for flow cytometric analysis on a FACSCalibur or a
FACScan (BD Biosciences). Events in a live lymphocyte gate were ana-
lyzed with CellQuest (BD Biosciences) software.
Ab treatment
For blockade of CTLA-4 interactions mice were given 0.5 mg of anti-
CTLA-4 Ab (23) (4F10; gift from M. van den Broek (University Hospital
Zurich, Zurich, Switzerland)) i.p. at the day of T cell transfer and two days
later. DCs were activated in vivo by i.p. injection of 50 g agonistic anti-
CD40 Ab (24) (FGK45.5; gift of J. Kirberg (University of Lausanne,
Epalinges, Switzerland)) 2 days before T cell transfer. Control mice
received PBS.
ELISA
Detection of IFN- and IL-17A was performed by ELISA (BD Bio-
sciences) on day 3 supernatants from in vitro restimulated T cell cultures.
2D2 CD4 T cells were reisolated 5 days after adoptive transfer to wild-
type or BMOG mice by MACS using CD90.1-PE Ab (BD Biosciences) and
anti-PE beads (Miltenyi Biotec) and cultured with MOG-pulsed wild-type
APCs in the absence or presence of MOGp35–55 (10 g/ml).
RNA analysis
For RNA analysis, total RNA from flow cytometry-sorted cells
(CD4Thy1.1) was isolated using the Qiagen mini kit according to the man-
ufacturer’s instruction. The expression of mRNA for Caspase-8, FADD, Bim,
Bid, Bax, Puma, and c-Flip was analyzed with specific primers from Qiagen
as described on their homepage (https://www1.qiagen.com/GeneGlobe/
Default.aspx) using the QuantiTect SYBR Green RT-PCR Kit. Expression
was normalized to that of the housekeeping gene GAPDH.
Induction and assessment of EAE
MOG35–55 peptide (amino acid sequence: MEVGWYRSPFSRVVH-
LYRNGK) was obtained from Research Genetics. Active EAE was in-
duced by immunization with 50 g of MOG35–55 peptide emulsified in
CFA (Difco Laboratories) supplemented with 8 mg/ml of heat-inactivated
Mycobacterium tuberculosis H37RA (Difco Laboratories). The emulsion
was administered as a 100 l s.c. injection in the tail base. Mice also
received 200 ng of pertussis toxin (Sigma-Aldrich) i.p. on the day of im-
munization and 2 days later. Passive EAE was induced by injection of
MOG-reactive lymphocytes (30 106/mouse, generated as described (25).
Mice also received 200 ng of pertussis toxin i.p. on the day of immuniza-
tion and 2 days later. For induction of EAE with spinal cord (sc) homog-
enate, sc from C57BL/6 mice was isolated and a 1g/1 ml sc in 0.9% (w/v)
NaCl homogenate was made by several passages through a syringe with
needles of decreasing diameter. The homogenate was emulsified in CFA to
a final ratio (v/v) of 1:1. The emulsion was administered as a 100 l s.c.
injection in the tail base. Mice also received 200 ng of pertussis toxin i.p.
on the day of immunization and 2 days later. Clinical assessment of EAE
was performed daily according to the following criteria: 0, no disease; 1,
decreased tail tone; 2, abnormal gait (ataxia) and/or impaired righting re-
flex (hind limb weakness or partial paralysis); 3, partial hind limb paralysis;
4, complete hind limb paralysis; 5, hind limb paralysis with partial fore
limp paralysis; and 6, moribund or dead.
In vivo depletion of CD25 cells
Endogenous CD25 cells were depleted from mice 2 days before induction
of EAE by i.p. injection with 1 mg of anti-CD25 Ab PC61 (rat IgG1).
Control mice received an i.p. injection of 1 mg of MAC49 (rat IgG1,
anti-phytochrome). Confirmation of CD25 cell depletion by PC61 was
determined by staining peripheral blood of all mice 2 days after treatment
with an Ab that recognizes a different epitope of CD25 (7D4), and it re-
sulted in 90% CD25 cell depletion (data not shown).
Statistics
Values are presented as mean SEM. Statistical significance was assessed
using 2-tailed Student’s t test. p values 0.05 were regarded significant.
Results
A new genetic system to investigate peripheral tolerance
To better understand the in vivo function of naive B cells in the
induction of tolerance and regulatory mechanisms, we generated
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a new mouse model that allows the cell-specific presentation of
MOGp35–55 on MHC class II. We constructed a mutated invariant
chain (Ii) where we replaced the sequence of the CLIP peptide by
the peptide sequence of MOGp35–55, resulting in the IiMOG gene
(Fig. 1A). To express the IiMOG gene in a tissue-specific manner, it
was inserted in the ROSA26 locus by homologous recombination as
it has previously been shown for the diphtheria toxin receptor gene
(26). The IiMOG gene was placed under the control of the ROSA26
promoter following a loxP flanked transcriptional STOP cassette (see
schematics in Fig. 1B). The STOP cassette prevents expression of the
IiMOG gene, as shown previously for the diphtheria toxin receptor
gene (26). We crossed the IiMOG knock-in mice to a mouse strain
that expresses the Cre-recombinase early in embryogenesis (deleter-
Cre) (27), resulting in mice that express the IiMOG gene in all cells
including all APCs (mice termed APCMOG). In APCMOG mice, all
cells that express MHC class II should present the MOG peptide (see
schematics in Fig. 1, A and B). To determine whether cells isolated
from APCMOG mice could present MOGp35–55 after removal of the
STOP cassette, we prepared bone marrow (BM)-derived dendritic
cells (DCs) from wild type (WT) mice, mice that still contained the
STOP cassette in the genome (STOPMOG mice), and from APCMOG
mice. These cells were cultured with CFSE-labeled MOG-specific
TCR transgenic CD4 T cells (termed 2D2 CD4 T cells; Ref. 18).
As seen in Fig. 1C, only DCs derived from BM of APCMOG mice, but
not of WT or of STOPMOG mice could induce proliferation of 2D2
CD4 T cells. This indicates that the IiMOG-encoded MOG peptide
is indeed loaded onto MHC class II molecules and efficiently pre-
sented to T cells. In addition, these data show that the STOP cassette
FIGURE 1. A, Scheme of the IiMOG system. The
CLIP peptide of the invariant chain (Ii) was replaced by
the sequence of MOGp35–55. Cleavage of the mutant Ii
(IiMOG) leads to the presentation of MOGp35–55 on
MHC class II on the cell surface. B, General scheme of
the IiMOG mouse strain. IiMOG is expressed under the
Gt(ROSA)26Sor/ROSA26 promoter only upon Cre-me-
diated removal of a STOP cassette. The STOP cassette,
which prohibits IiMOG expression, is removed by
crossing the IiMOG strain to a specific Cre-expressing
mouse strain. C, To prove functionality of the IiMOG
system BM-derived DCs from WT, STOPMOG, and
APCMOG mice were cultured with CFSE-labeled MOG-
specific 2D2 CD4 T cells either with (right histogram)
or in the absence (left histogram) of externally added
MOGp35–55. Five days later cells were monitored for
proliferation. DCs from the different mice are indicated
with different lines in the histogram. D, Specific presen-
tation of MOGp35–55 on B cells is achieved by crossing
of the IiMOG strain to B cell-specific CD19-Cre mice.
E, To show specificity of MOGp35–55 presentation by
B cells, DCs, M, and B cells from BMOG mice were
cultured with CFSE-labeled 2D2 CD4 T cells either
with (right histogram) or in the absence (left histogram)
of externally added MOGp35–55. The different APCs are
indicated with different lines in the histogram. IiMOG, mu-
tant invariant chain (containing MOGp35–55 instead of the
CLIP peptide); triangles, loxP sites; arrows, transcriptional
activity; open ovals, promoter.
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is stringent, not allowing expression of IiMOG before its excision by
Cre-recombinase.
Next, the B cell-specific deletion of the STOP cassette was in-
vestigated by crossing the IiMOG allele to B lymphocyte-specific
CD19-Cre mice (20) (Fig. 1D). From double-transgenic mice
(termed BMOG), B cells, macrophages, and DCs were isolated and
cultured separately with CFSE-labeled 2D2 CD4 T cells for 5
days. As shown in Fig. 1E, only B cells, but not DCs or macro-
phages from BMOG mice induced proliferation of T cells in vitro.
Upon addition of external MOGp35–55, either macrophages or
DCs could support T cell proliferation, indicating that these are
indeed proficient APCs (Fig. 1E).
B cells induce tolerance and protect from the induction of CNS
inflammation
Because we could show that the B cells in BMOG mice presented
the MOG peptide and could induce moderate proliferation of
MOG-specific T cells in culture, it was of interest to investigate
whether these mice are susceptible to MOG-induced EAE. As seen
in Fig. 2A, BMOG mice as well as APCMOG mice are resistant to
EAE upon immunization with MOGp35–55 in CFA. We reasoned
that BMOG mice are resistant to EAE induction due to the B cell-
specific presentation of MOGp35–55 in vivo, which could lead
either to central tolerance in the thymus, if indeed B cells can
participate in this process, or to peripheral tolerance.
FIGURE 2. Ag presentation by naive B cells induces tolerance to EAE. A, EAE was actively induced by immunization of BMOG (F), APCMOG (),
or WT mice (f) with MOGp35–55. BMOG and APCMOG mice develop significantly less severe EAE compared with WT mice (p  0.05, days 13–28).
Shown is one representative of two individual experiments (n  5 mice/group). B, MOG-specific 2D2 CD4 T cells were adoptively transferred into BMOG
(F) or WT mice (f). After 1 wk, EAE was actively induced by immunization with MOGp35–55 including untreated WT control mice (Œ). BMOG mice
develop significantly less severe EAE than WT mice (p  0.05). Shown is one representative of two individual experiments (n 	 6 mice/group). C, EAE
was induced by adoptive transfer of MOG-reactive lymphocytes into BMOG (F) or WT mice (f). BMOG mice develop significantly less severe EAE than
WT mice (p  0.05). Shown is one representative of two individual experiments (n 	 6 mice/group). D, EAE was actively induced in WT mice 2 days
after transfer of B cells from WT (), from BMOG (E), activated B cells from BMOG mice (F), or without transfer of B cells (f). Mice injected with naive
or activated BMOG B cells developed significantly less severe EAE compared with untreated WT or WT-B cell-injected mice (p  0.05). E, EAE was
actively induced in WT mice and 12 days after immunization, B cells from BMOG mice (F) were transferred. Control mice received PBS (f). Mice injected
with naive BMOG B cells developed significantly less severe EAE compared with PBS-treated control mice (p  0.05; days 16–32). F, EAE was induced
in BMOG (F) or WT mice (f) by immunization with spinal cord homogenate. Values are represented as mean  SEM.
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To investigate whether B cells are involved in the process of
peripheral tolerance, resulting in resistance to MOG-induced EAE
in BMOG mice, we adoptively transferred 2D2 CD4 T cells to
BMOG mice, and actively induced EAE 1 wk later. As seen in Fig.
2B, the transfer of naive MOG-specific T cells did not bypass the
resistant phenotype of BMOG mice. In contrast, WT mice, which
received 2D2 CD4 T cells, were as susceptible to EAE as control
WT mice that had not received 2D2 CD4 T cells. Furthermore,
we adoptively transferred MOG-reactive lymphocytes from
C57BL/6 mice to induce passive EAE in BMOG as well as WT
mice. We observed that BMOG mice were also resistant to passive
EAE induction (Fig. 2C).
We showed that the specific presentation of MOG peptide by B
cells renders the BMOG mice resistant to EAE that was actively
induced by the presented peptide or by passive transfer of enceph-
alitogenic MOG-reactive T cells. We reasoned that the MOG-spe-
cific T cells are able to interact with the MOG-presenting B cells,
but as a consequence of this interaction the T cells are anergized
and thus unable to induce EAE. To investigate whether tolerance
can be induced also by transfer of MOG-presenting B cells, we
injected isolated B cells from BMOG to WT C57BL/6 mice and
induced active EAE 2 days later. We observed that mice injected
with MOG-presenting B cells developed only a mild form of EAE
compared with WT or WT-B cell-injected control mice (Fig. 2D).
Interestingly, mice injected with activated MOG-presenting B cells
(before transfer B cells were activated in vitro with anti-CD40,
anti-BCR, and IL-4) were also resistant to EAE (Fig. 2D). B cell
transfer to EAE mice on day 12 after immunization results in sig-
nificantly less severe EAE compared with PBS-treated control
mice (Fig. 2E). Thus, we conclude that also transferred MOG-
presenting B cells have the capacity to induce tolerance to
MOG-induced EAE.
Because the presentation of MOGp35–55 by B cells induced
tolerance to EAE, it was of interest to investigate whether BMOG
mice develop disease when encountering all immunogenic
epitopes of the myelin sheath or whether tolerance induced by
MOG-presenting B cells is dominant. To this end, BMOG and WT
mice were immunized with C57BL/6 sc homogenate covering all
immunogenic epitopes of the myelin sheath. Upon immunization
with sc homogenate, BMOG mice developed EAE to the same ex-
tent as WT mice (Fig. 2F), indicating that tolerance induced by B
cells presenting MOGp35–55 is not dominant.
Activation of T cells by B cells does not lead to clonal
expansion
Targeting of Ag to immature DCs was previously shown to induce
the formation of regulatory T cells (Tregs) in vivo (28). To inves-
tigate if presentation of the MOG peptide by B cells will induce
conversion of naive T cells to Tregs, we analyzed the population
of Foxp3 T cells in BMOG mice. As demonstrated in Fig. 3A, we
could not detect an obvious change in the percentage of Foxp3 T
cells among CD4 T cells in these mice. As it was previously
demonstrated that B-T cell interactions can lead to the develop-
ment of Tregs (29), it is possible that MOG-presenting B cells
induce the development of MOG-specific Treg cells which might
be responsible for the tolerance we observe. Because the number
of specific Tregs is relatively small, it may not be possible to detect
this change in the total Foxp3 population. To investigate whether
elevated levels of MOG-specific Tregs contribute to the resistance
to EAE in BMOG mice, we depleted endogenous CD25 cells by
injection of anti-CD25 Ab (PC61) before induction of EAE. It was
reported that Foxp3CD25 are depleted by this treatment (30).
The depletion of CD25 T cells does not change the resistant
phenotype of BMOG compared with isotype-treated BMOG mice
(Fig. 3B). As expected, WT mice treated with anti-CD25 before
EAE induction developed disease of increased severity compared
with isotype-treated WT controls (Fig. 3B). These results indicate
FIGURE 3. Tolerance of BMOG mice is not due to
enhanced Treg cell levels. A, Intracellular staining for
Foxp3 on MACS-purified CD4 T cells from WT and
BMOG mice. B, WT (square) and BMOG (circle) mice
were injected with 1 mg of PC61 (open symbols) or
isotype control Ab (MAC49; filled symbols). EAE was
induced by immunization 2 days later. BMOG mice were
resistant to EAE, also after PC61 treatment, whereas
WT mice developed significantly more severe EAE
compared with isotype control injected WT mice (p 
0.05, days 13–26).
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that CD4CD25 T cells are not involved in the resistance to EAE
of BMOG mice.
To better follow the effect of B cell-specific presentation of
MOGp35–55 on MOG-specific T cells, we labeled 2D2 CD4
T cells with CFSE and adoptively transferred them to BMOG,
APCMOG, and WT mice. Five days after transfer, different lym-
phoid organs were isolated and proliferation of the transferred T
cells was monitored, as depicted by the loss of CFSE labeling.
MOG-specific T cells divided extensively after in vivo encounter
of MOG-presenting APCs in APCMOG mice (Fig. 4A). No division
of T cells transferred to WT mice was seen. This lack of division
was expected because in the absence of Ag, or space for homeo-
static proliferation, T cells do not divide (31, 32). In contrast to
APCMOG mice, 2D2 CD4 T cells transferred to BMOG mice
hardly proliferated within the period of 5 days (Fig. 4A). Also,
activation of the MOG-presenting B cells in BMOG mice with anti-
CD40 did not result in enhanced proliferation of transferred MOG-
specific T cells (data not shown).
We were interested to assess whether the lack of proliferation of
T cells is a consequence of their naive state, and whether activated
or memory T cells will proliferate after interaction with B cells.
2D2 TCR transgenic mice were immunized with MOGp35–55 in
CFA. Ten days later, CD4 T cells were purified (activated T
cells) and transferred to WT, BMOG, or APCMOG mice. For induc-
tion of memory T cells, activated 2D2 CD4 T cells were trans-
ferred and left for 1 mo in MOG-deficient mice (22), assuming that
in the period of 30 days in which the cells are not further activated,
a large proportion of the transferred T cells differentiated to mem-
ory cells. Proliferation of activated and memory 2D2 CD4 T cells
was analyzed 5 days after transfer. As seen in Fig. 4A, also acti-
vated 2D2 T cells did not proliferate in BMOG mice. In contrast,
memory T cells proliferated to a similar extent as in APCMOG
mice. We conclude that B cells have the capacity to induce pro-
liferation of Ag-experienced resting T cells, but not of naive or
recently activated T cells.
Although MOG-specific T cells hardly proliferated upon inter-
action with MOG-presenting B cells, we observed one up to two
cycles of proliferation and wondered if we could detect expression
of activation markers on these cells. As seen in Fig. 4B, T cells do
FIGURE 4. MOG-specific T cells show a tolerized phenotype after interaction with MOG-presenting B cells. A, Proliferation of naive (upper row),
activated (middle row), or memory (lower row) 2D2 CD4 T cells, 5 days after adoptive transfer to WT (left panel), BMOG (middle panel), or APCMOG
mice (right panel). Numbers in histograms indicate percent positive cells in each marker region. Data are representative of three independent experiments.
B–D, FACS analysis of 2D2 CD4 T cells 5 days after transfer to WT (black line), BMOG (red line), or APCMOG mice (blue line). Stainings were performed
using Abs to CD44, CD69, and Ly6C (B) or CTLA-4, PD-1, BTLA, CD4, Tim-3, and Fas (C) or CD25, CD103, Gitr, and Foxp3 (D). E, Secretion of IFN-
(upper diagram) and IL-17A (lower diagram) was detected performing ELISA on SN from 2D2 CD4 T cells transferred to WT (f) or BMOG () mice,
72 h after restimulation with MOGp35–55 in vitro. n.d., not detectable.
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not up-regulate expression levels of CD69 and CD44, after inter-
action with B cells, but interestingly, they down-regulate the ex-
pression of Ly6C. In contrast, following interaction with B cells
presenting their cognate Ag, T cells up-regulate the expression
levels of the coinhibitory molecules CTLA-4, PD-1, BTLA, and
CD5 (Fig. 4C). We could not detect differences in the expression
levels for Tim-3 and Fas between unactivated T cells and T cells
that interacted with B cells (Fig. 4C).
Also, expression of receptors and markers normally up-regu-
lated on surface of Treg cells was unaltered (Fig. 4D). When ac-
tivating 2D2 CD4 T cells with the MOG peptide in culture, T
cells that had interacted with their cognate Ag presented in vivo by
B cells did not secrete IFN- or IL-17A, indicating that these cells
are functionally tolerized (Fig. 4E).
IL-10 does not play a role in tolerance induced by B cells
How do B cells induce tolerance? Recently, it was shown that
IL-10 specifically produced by B cells is active at the remission
stage of EAE and allows the mice to recover from disease (33).
According to that study, it is essential that B cells produce IL-10,
otherwise recovery from EAE cannot occur, similar to B cell-de-
ficient mice (33). It is not clear from that study at which phase of
disease B cell-produced IL-10 is functional: is it at the stage of T
cell activation or do IL-10-producing B cells indeed invade the
brain and directly tolerize encephalitogenic T cells? Because in-
duction of EAE is similar in WT and B cell-IL-10-deficient mice
(33), it is also not clear whether IL-10 produced by B cells has a
general role in tolerance to EAE or only in causing remission. To
investigate whether the tolerization by B cells is associated with
their production of IL-10, presentation of MOG by IL-10-deficient
B cells was achieved by crossing the BMOG mice to mice that allow
the tissue-specific deletion of the il-10 gene (IL-10fl; (34). The
il-10 gene is efficiently inactivated in IL-10fl/fl/CD19-Cre mice
(A.R. and W.M., manuscript in preparation). 2D2 CD4 T cells
were transferred to these mice (termed BMOG/IL-10fl/fl mice) and
proliferation of the T cells was assessed 5 days after transfer. As
seen in Fig. 5A, the presentation of MOG by IL-10-deficient B
cells did not lead to an enhanced proliferation of MOG-specific T
cells, indicating that the production of IL-10 by B cells had no role
in tolerance of T cells, when the peptide was presented by B cells.
Consistently, BMOG/IL-10fl/fl mice showed similar resistance to
MOG-induced EAE as BMOG mice (Fig. 5B).
B cells mediate their tolerance effect via CTLA-4 and PD-1
It was previously shown that PD-1 plays a role in the induction of
peripheral tolerance of CD8 T cells by resting DCs (35). In Fig.
4, we demonstrated that MOG-presenting B cells induced an up-
regulation of CD5, BTLA, PD-1, and CTLA-4 by MOG-specific T
cells. To assess the contribution of CD5, we investigated whether
injection of anti-CD5 Ab could prevent induction of T cell toler-
ance by MOG-presenting B cells. No difference in proliferation
ensued when CD5 was blocked (data not shown). To reveal
whether PD-1 is required for the induction of CD4 T cell toler-
ance in our system, PD-1-deficient mice were crossed to 2D2 mice
to obtain MOG-specific T cells that cannot interact through PD-1.
Before transfer, PD-1/ 2D2 T cells were analyzed for the trans-
genic CD4 T cell population and displayed no obvious difference
compared with WT 2D2 mice (data not shown). To investigate the
involvement of CTLA-4 in B cell-induced CD4 T cell tolerance,
recipient mice were treated with a mAb that blocks signaling
through CTLA-4 in vivo (23, 35). Either WT or PD-1/ trans-
genic 2D2 CD4 T cells (Thy1.1) were CFSE-labeled and adop-
tively transferred to BMOG and WT mice (Thy1.2). Recipient mice
were additionally treated with anti-CTLA-4 or PBS, and the trans-
ferred T cells were monitored for proliferation. The treatment of
recipient BMOG mice with anti-CTLA-4 as well as the transfer of
PD-1/ 2D2 T cells led to an increase in proliferation of the
transferred T cells up to 71 and 79%, respectively (Fig. 6). The
combination of PD-1 deficiency and blockade of CTLA-4 led to a
higher increase in proliferation up to 97% of total proliferating T
cells, with most cells dividing at least twice (Fig. 6), which indi-
cates that both PD-1 and CTLA-4 play an important role in the
induction of peripheral CD4 T cell tolerance by naive B cells.
Further, the importance of PD-1 and CTLA-4 was shown by in-
ducing EAE in anti-CTLA-4-treated PD-1/ mice upon transfer
of BMOG B cells. The percentage of paralysis after transfer of
BMOG B cells increased from 0% in WT mice to 33% in anti-
CTLA-4-treated PD-1/ mice, respectively (Fig. S1).4 These
data demonstrate that the tolerance mediated by B cells is partially
dependent on PD-1 and CTLA-4.
B cells induce peripheral tolerance by sensitizing T cells to
Ag-induced cell death
To investigate how B cell-anergized T cells react to restimulation
in vivo, 2D2 CD4 T cells (Thy1.1) were adoptively transferred to
4 The online version of this article contains supplemental material.
FIGURE 5. The tolerization of MOG-specific T cells by B cells is in-
dependent of IL-10. A, Proliferation of naive 2D2 CD4 T cells 5 days
after transfer to CD19-Cre/IL-10fl/fl, BMOG/IL-10fl/, BMOG/IL-10fl/fl, and
APCMOG mice. Cells were gated on Thy1.1 cells. Numbers in quadrants
indicate percent positive cells in each. B, EAE was actively induced by
immunization of control (WT, IL-10fl/ and IL-10fl/fl mice; ()), BMOG
(F), or BMOG/IL-10fl/fl () mice with MOGp35–55. BMOG and BMOG/
IL-10fl/fl mice develop significantly less severe EAE compared with
control mice (p  0.05, days 14 –26). Values are represented as mean 
SEM.
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BMOG or WT mice (Thy1.2). Then, total CD4 T cells were rei-
solated from the recipients 5 days after transfer, labeled with CFSE
and transferred into APCMOG mice (Thy1.2), which were injected
with agonistic anti-CD40 to activate DCs in vivo (as depicted in
the scheme of Fig. 7A). Before transfer, we determined the ratio
between Thy1.1 2D2 T cells and Thy1.2 host CD4 T cells.
Because the 2D2 T cells did not proliferate extensively in either of
the hosts, as demonstrated in Fig. 4A, the ratio was similar, namely
1:12 for Thy1.1 vs Thy1.2 cells (Fig. 7B). As seen in Fig. 7C,
2D2 CD4 T cells that were transferred to WT mice, reisolated,
and transferred to APCMOG mice proliferated extensively, to a
similar extent as when directly transferred to APCMOG mice (Fig.
4A). The transferred Thy1.2 CD4 WT host T cells are CFSE,
but do not proliferate, as they are not MOG-specific, and serve in
this study as an internal control for proliferation and ratio changes.
Thus, we showed that transfer of 2D2 CD4 T cells to WT mice
does not alter their potential to be activated as seen when reisolated
and transferred to APCMOG mice. In contrast, 2D2 CD4 T cells
that first encountered MOG by B cells in BMOG mice and were
then transferred to APCMOG mice were dramatically decreased in
number. As seen in Fig. 7C, only very few Thy1.1 T cells were
left after in vivo restimulation, indicating that T cells initially trig-
gered by B cells are rendered sensitive to deletion upon a second
exposure to Ag on activated APC in vivo. The ratio of Thy1.1 to
Thy1.2 cells among all CD4 T cells originally reisolated from
WT mice was 
1:1 (Fig. 7, C and D). In contrast, the ratio of
Thy1.1 to Thy1.2 cells among all CD4 T cells was 
1:12
when CD4 T cells were transferred to BMOG before transfer to
APCMOG mice, although Thy1.1 cells appeared to proliferate in
APCMOG mice. These results indicate that 2D2 CD4 T cells that
were reisolated from WT mice as well as the ones reisolated from
BMOG mice were triggered and proliferated when restimulated in
APCMOG mice. In contrast to 2D2 CD4 T cells that never en-
countered Ag before, 2D2 CD4 T cells that encountered MOG on
B cells died upon activation, most likely after proliferation was
FIGURE 6. PD-1 deficiency and blockade of CTLA-4 partially rescue T
cells from tolerance. Proliferation of naive WT 2D2 CD4 (left row) or
PD-1/ 2D2 CD4 T cells (right row) 5 days after adoptive transfer to
anti-CTLA-4-treated (lower row) or untreated (upper row) BMOG mice.
Numbers in quadrants indicate percent positive cells in each. MFI, mean
fluorescence intensity.
FIGURE 7. BMOG-tolerized T cells are deleted upon restimulation in vivo. A, Schematic presentation of the experiment. B, Ratio of 2D2 CD4 Thy1.1
vs WT Thy1.2 CD4 5 days after transfer to WT or BMOG mice. C, Proliferation of 2D2 CD4Thy1.1 T cells reisolated from WT or BMOG mice after
restimulation for 4 days in anti-CD40 injected APCMOG mice. Cells were gated on Thy1.1 and CFSE cells. Numbers close to gates refer to events and
percentage of positive cells in each. D, Ratio values of CFSE-labeled 2D2 CD4 Thy1.1 vs WT Thy1.2 CD4 4 days after restimulation in anti-
CD40-injected APCMOG mice.
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initiated, as no nonproliferating Thy1.1 T cells could be detected
(Fig. 7C).
In view of our data, we suggest a model, in which the interaction
of T cells with Ag-presenting B cells leads to partial activation of
the T cells. This is manifested by their marginal proliferation, by
the absence of expression of activation markers, but also by the
expression of coinhibitory molecules. T cells that interact with
more potent APCs, as in APCMOG mice, will expand and contrib-
ute to the pool of effector T cells. Both types of T cell activation,
i.e., following interaction with B cells or DCs in vivo, will
ultimately lead to AICD once the cells are retriggered by potent
APCs (Fig. 7).
FIGURE 8. MOG presentation by B cells enhances Bax and decreases c-Flip expression by MOG-specific T cells. Real-time PCR for Caspase-8, Bim,
Bid, FADD, Puma, Bax, and c-Flip was performed on mRNA from 2D2 CD4 T cells sorted 5 days after transfer to WT (f) or BMOG () mice.
FIGURE 9. PD-1 deficiency and blockade of
CTLA-4 do not rescue tolerized T cells from deletion.
Proliferation of 2D2 CD4Thy1.1 T cells reisolated
from WT or BMOG mice after restimulation for 4 days in
anti-CD40-injected APCMOG mice. On the day of the
second transfer and 2 days later, mice were additionally
injected with anti-CTLA-4 in combination with (right
panel) or without (middle panel) PD-1 deficiency. Cells
were gated on Thy1.1 and CFSE cells. Numbers
close to gates refer to percentage of positive cells in
each. MFI, mean fluorescence intensity.
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RNA was prepared from sorted 2D2 T cells 5 days after transfer
to BMOG or WT mice. The RNA was subjected to real-time RT-
PCR using primers specific for the proapoptotic molecules
Caspase-8, FADD, Bim, Bid, Bax, Puma, and the anti-apoptotic
molecule cellular FLICE-inhibitory protein (c-Flip). A significant
difference was only found in the increased expression of Bax and
the decreased expression of c-Flip (Fig. 8). The increase of Bax
and the reduction in c-Flip expression levels may render the cells
sensitive to apoptosis, since c-Flip is able to modulate activation of
procaspase-8 and thereby prevents induction of apoptosis mediated
by death receptors (36) whereas Bax is required for mitochondrial
dysfunction during apoptosis (37).
We could show that the interaction of T cells with B cells in-
duces only modest T cell proliferation, but the expression of neg-
ative costimulatory molecules. Further, we noted that this interac-
tion supported T cell proliferation when signaling through PD-1
and CTLA-4 was blocked (Fig. 6). To investigate whether block-
ing the signaling through these molecules might have an effect on
AICD, we performed similar in vivo restimulation experiments as
seen in Fig. 7, using PD-1/ T cells and treatment with anti-
CTLA-4. Then, the T cells were CFSE-labeled and transferred to
APCMOG mice as already demonstrated in Fig. 7. The tolerized T
cells were not rescued from deletion when signaling via CTLA-4
and PD-1 was blocked (Fig. 9).
Discussion
In this study, we show that constitutive Ag presentation by B cells
on MHC class II (MHCII) results in profound peripheral tolerance.
We have shown that T cells that specifically interact with B cells
in vivo are partially activated, but this activation does not lead to
their proliferation. Rather, they up-regulate the expression of coin-
hibitory molecules and become highly sensitive to AICD. The pro-
cess we propose in this study is a part of general peripheral toler-
ance: we suggest that in the steady state, CD4 T cells that
recognize their specific Ag presented by B cells undergo a process
that eventually results in their death once these T cells recognize
the Ag in a more potent antigenic context. As B cells are the most
prevalent MHCII-expressing cells in the body, they are the natural
candidates to serve as cells that enforce tolerance of autoreactive
CD4 cells, once these cells develop and migrate from the thymus
to the periphery. In this study, we demonstrate a central role for B
cells in preventing autoimmune responses that are mediated by
MHCII-restricted T cells.
Using the Cre/loxP system, we were able to direct the expres-
sion of the MOG peptide p35–55 specifically to B cells. This sys-
tem ensures B cells to be able to interact with Ag-specific T cells
in all secondary immune organs. We found that in contrast to the
specific presentation of MOG by B cells, its presentation by all
MHCII cells, including macrophages and different DC popula-
tions, enables MOG-specific T cells to proliferate extensively. This
finding indicates that the tolerance mediated by B cells is not dom-
inant over other APCs; in a system that allows peptide presentation
not only by B cells, but by all MHCII cells, the latter can nev-
ertheless induce T cell proliferation.
Tolerance induced by B cells is profoundly different to that
induced by DCs or other professional APCs. When DCs present
peptide to CD4 T cells following injection with DEC205/pep-
tide conjugate, the T cells first go through a phase of abortive
proliferation (28, 38). Likewise, when mice are rendered toler-
ant by i.v. injection with peptide, the T cells first go through a
few cycles of proliferation before their deletion that results in
tolerance to EAE (39, 40). B cells therefore provide a more
efficient form of tolerance compared with DCs. This tolerance
takes less immunological space, as the Ag-specific T cells to not
need to be expanded and then eliminated. In contrast to DCs, B
cells provide a more economical tolerance mechanism, by
which the T cells do not need to go first through a phase of
abortive proliferation, but are rendered sensitive to elimination
upon further activation, when it is done in a more physiological
context.
BMOG as well as APCMOG mice are resistant to active EAE
induction. As a result of IiMOG expression in the thymus,
MOG-specific T cells could be eliminated, resulting in mice that
lack the MOG-specific T cell repertoire. Although B cells are
not normally implicated in the process of negative selection,
their presence in the thymus was shown before (41). Therefore
it is possible that both MOG-expressing mouse strains are re-
sistant to EAE due to central tolerance. Thus, we have used
MOG-specific T cells isolated from IiMOG-negative mice and
shown that also these cells, although they were not subjected to
central tolerance by MOG, were not able to induce EAE in
BMOG mice.
The interaction of B cells with naive as well as activated
MOG-specific T cells did not result in massive proliferation of
the T cells, which is seen when these cells are activated by DCs
and macrophages in APCMOG mice. However, activation of
resting Ag-experienced T cells by B cells was indistinguishable
from activation of these cells in APCMOG mice. These data
indicate that B cells do not support the expansion of naive or
activated T cells, but do induce proliferation of memory T cells.
These findings also support the dogma, according to which
memory T cells require less stimulation for their activation,
which could also be supplied by B cells (1). It is possible that
naive B cells do not express the costimulatory molecules that
are necessary for the activation of naive or activated T cells, but
the conditions needed for the activation of memory T cells are
lower and therefore they can be activated by B cells. On the
other hand, we have performed experiments in which the B cells
of BMOG mice were activated in vivo using LPS or anti-CD40,
but naive T cells transferred to these mice were not sufficiently
stimulated to proliferate. It has previously been shown that ac-
tivated transferred B cells need to express B7 molecules to in-
duce tolerance (10). It is possible that, in our system, tolerance
can also be achieved by costimulatory molecules other than B7.
This raises the possibility that B cells have to be activated by
cognate Ag in conditions that differ from these given by TLRs
or the CD40 receptor to efficiently activate naive T cells.
Studies by several groups demonstrated that B cells do in-
teract with T cells in culture, resulting in proliferation of the T
cells (42) or even their conversion into Tregs (29, 43). B cells
isolated from BMOG mice are able to induce moderate prolifer-
ation of naive T cells in culture without the addition of exog-
enous Ag. Possibly, when both cell types are present in close
proximity in tissue culture conditions, B cells form a stable long
term interaction with T cells that could lead to their prolifera-
tion and/or differentiation into Tregs (29). Our present work
does not contradict such a possible function of B cells. We
suggest that in vivo, the main process by which B cells con-
tribute to peripheral tolerance is via sensitization of self-reac-
tive T cells to AICD. These results are also support by the
previous work of Townsend and Goodnow (44). The latter work
demonstrated that B cells can stimulate rare Ag-specific T cells
resulting in abortive proliferation of the T cells (44). It is also
possible that in BMOG mice some of the T cells differentiate into
Tregs, as has been shown following the interaction of naive T
cells with steady-state DCs (28). Although we did not notice a
general elevation of FoxP3 T cells and the deletion of CD25
Tregs in BMOG mice did not alter their resistant phenotype, we
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cannot answer this question with certainty without using re-
agents that can specifically label MOG-specific T cells in BMOG
mice. Previously, it was shown that depletion of Treg cells ab-
rogated tolerance induced by transfer of activated B cells (45).
These results do not contradict with our findings since our data
do not imply that B cells do not induce the generation of Tregs,
but indicate that the B cell-mediated tolerance by directly in-
hibiting effector T cells is dominant over tolerance mediated by
the generation of Tregs, or at least is sufficient for the inhibition
of EAE induction.
Deletion of the B cell-tolerized T cells occurs upon in vivo
reactivation and is contrary to studies by Seamons et al. (42)
showing less proliferation but no deletion of T cells that were
restimulated by B cells. The fact that they use bulk cultures and
ex vivo stimulation might account for the discrepancy to our
data. Our results do not explain how B cells are able to interact
with T cells during a germinal center reaction without the toler-
ization of these T cells. Germinal center B cells possibly behave
different from naive or even LPS-stimulated B cells and may
down-regulate negative costimulatory receptors that are respon-
sible for the general T cell tolerance observed in BMOG mice.
Previously, Fillatreau and colleagues demonstrated that IL-10
produced by B cells has a suppressive role in EAE, and when B
cells were incapable to produce this cytokine, mice could not
recover from the disease (33). Moreover, B cell-produced IL-10
has been shown to play an important role in the prevention of
arthritis (46) (47). In the present work, we could demonstrate
that B cells are able to serve as suppressor cells in the initiation
of the disease. Also, transfer of MOG-presenting B cells after
disease onset significantly attenuated the course of EAE, dem-
onstrating a suppressive potential of B cells, as it is especially
challenging to reverse ongoing EAE. Using mice in which B
cells presented the MOG peptide, but were not able to produce
IL-10, we could show that the effect of peripheral tolerance that
is mediated by B cells is independent from their IL-10
production.
Studies by the groups of Y. Ron and D. Scott (6–9) have pre-
viously shown that B cells can efficiently serve as tolerogenic cells
that prevent the induction of EAE or even serve as a therapy in a
relapsing-remitting model of the disease. We have now extended
these studies by using a chronic model of EAE and a mouse strain
that allows Ag presentation by B cells that were not manipulated
in culture or applied by transfer. Importantly, we could show
that the mechanism by which B cells mediate the process of
peripheral tolerance involves the coinhibitory receptors PD-1
and CTLA-4. These studies are important in the designation of
future cell-based therapies for autoimmune diseases, as B cells
of patients are easy to obtain and manipulate.
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